Elaine Hylek | Profiles RNS

Elaine M. Hylek, MD

Professor

Boston University Chobanian & Avedisian School of Medicine

Medicine

General Internal Medicine

MD, University of Pittsburgh School of Medicine
MPH, Harvard School of Public Health
MS, University of Pittsburgh
BS, Pennsylvania State University

Websites

	Boston Medical Center Provider Profile
	Whitaker Cardiovascular Institute's Training Program
	ResearchGate

ORCID : 0000-0001-8263-8304

Expertise includes: Arterial Thrombosis; Venous Thrombosis; Atrial Fibrillation; Safety and Effectiveness of Antithrombotic Therapy.

Member
Boston University
Evans Center for Interdisciplinary Biomedical Research

Personnel agreement for research services of Elaine M. Hylek
01/01/2012 - 12/31/2013 (PI)
Department of Veterans Administration, Bedford

Personnel Agreement for Research Services of Elaine Hylek
01/01/2011 - 12/31/2013 (PI)
Department of Veterans Affairs

Phase II Study - Development and Implementation of Clinical Practice Guidelines in a Large Teaching Hospital for the Use of Fragmin as Bridging Therapy
07/01/2005 - 06/30/2007 (PI)
Pfizer, Inc.

Anticoagulation Consortium to Improve Outcomes Nationally (ACTION) Registry
03/01/2005 - 02/28/2007 (PI)
Bristol-Myers Squibb

Differences in Baseline Patient Characteristics and Their Contribution to the Disparate Efficacy Conclusions of SPORTIF III and SPORTIF V
06/07/2005 - 12/06/2006 (PI)
AstraZeneca

Effectiveness and Safety of Antithrombotic Strategies after Joint Replacement
02/16/2011 - 01/31/2017 (PI)
NIH-NHLBI
5R01 HL106029-05

Effect of Statins and Modifiable Factors on Stroke Outcome in Atrial Fibrillation
09/30/2010 - 07/31/2015 (PI)
NIH-NINDS
5R01 NS070307-03

IPA Agreement - Guneet Jasuja
06/01/2013 - 08/31/2014 (PI)
VA

BRIDGE Trial
11/01/2009 - 10/31/2010 (PI)
Duke Clinical Research Inst NIH-NHLBI
U01 HL087229

Title

Yr	Title	Project-Sub Proj	Pubs
2015	Effectiveness and Safety of Antithrombotic Strategies after Joint Replacement	5R01HL106029-05	13
2014	Effectiveness and Safety of Antithrombotic Strategies after Joint Replacement	5R01HL106029-04	13
2013	Effectiveness and Safety of Antithrombotic Strategies after Joint Replacement	5R01HL106029-03	13
2012	Effectiveness and Safety of Antithrombotic Strategies after Joint Replacement	5R01HL106029-02	13
2012	Effect of Statins and Modifiable Factors on Stroke Outcome in Atrial Fibrillation	5R01NS070307-03	16
2011	Effectiveness and Safety of Antithrombotic Strategies after Joint Replacement	1R01HL106029-01	13
2011	Effect of Statins and Modifiable Factors on Stroke Outcome in Atrial Fibrillation	5R01NS070307-02	16
2010	Effect of Statins and Modifiable Factors on Stroke Outcome in Atrial Fibrillation	1R01NS070307-01A1	16

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Lim TW, Camm AJ, Virdone S, Singer DE, Bassand JP, Fonarow GC, Fox KAA, Ezekowitz M, Gersh BJ, Kayani G, Hylek EM, Kakkar AK, Mahaffey KW, Pieper KS, Peterson ED, Piccini JP. Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD-AF and ORBIT-AF registries. Clin Cardiol. 2023 Nov; 46(11):1398-1407. PMID: 37596725; PMCID: PMC10642328; DOI: 10.1002/clc.24109;

Go AS, Al-Khatib SM, Desvigne-Nickens P, Bansal N, Bushnell CD, Fang MC, Freeman JV, Gage BF, Hanke T, Hylek EM, Lopes RD, Noseworthy PA, Reddy VY, Singer DE, Thomas KL, True Hills M, Turakhia MP, Zieman SJ, Cooper LS, Benjamin EJ. Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. Stroke. 2023 Mar; 54(3):e75-e85.View Related Profiles.

Hylek, Elaine
Benjamin, Emelia

PMID: 36848427; PMCID: PMC9995163; DOI: 10.1161/STROKEAHA.121.038273;

Hylek EM. Catheter-Directed Treatment of Submassive Pulmonary Embolism-A Cautious Step Closer? JAMA Cardiol. 2022 Dec 01; 7(12):1197-1198. PMID: 36260318

Al-Khatib SM, Wojdyla DM, Granger CB, Wallentin L, Garcia DA, Hijazi Z, Held C, Alexander JH, Vinereanu D, Flaker GC, Hylek EM, Lopes RD. Duration of Anticoagulation Interruption Before Invasive Procedures and Outcomes in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial. Circulation. 2022 Sep 20; 146(12):958-960. PMID: 36121911

Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, Patel MR, Wallentin L, Alexander JH, Cecilia Bahit M, Benz AP, Bohula EA, Chao TF, Dyal L, Ezekowitz M, A A Fox K, Gencer B, Halperin JL, Hijazi Z, Hohnloser SH, Hua K, Hylek E, Toda Kato E, Kuder J, Lopes RD, Mahaffey KW, Oldgren J, Piccini JP, Ruff CT, Steffel J, Wojdyla D, Granger CB. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation. 2022 01 25; 145(4):242-255. PMID: 34985309; PMCID: PMC8800560; DOI: 10.1161/CIRCULATIONAHA.121.056355;

Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR, Mahaffey KW, Notani RS, Roberts R, Segers A, Raskob GE. Milvexian for the Prevention of Venous Thromboembolism. N Engl J Med. 2021 12 02; 385(23):2161-2172. PMID: 34780683; PMCID: PMC9540352; DOI: 10.1056/NEJMoa2113194;

Rasmussen PV, Hylek E. Persistence with treatment in atrial fibrillation: still a pressing issue in the era of direct oral anticoagulants. Eur Heart J. 2021 10 21; 42(40):4138-4140. PMID: 34347053

Albers GW, Bernstein R, Brachmann J, Camm AJ, Fromm P, Goto S, Granger CB, Hohnloser SH, Hylek E, Krieger D, Passman R, Pines JM, Kowey P. Reexamination of the Embolic Stroke of Undetermined Source Concept. Stroke. 2021 08; 52(8):2715-2722. PMID: 34192898

Pol T, Hijazi Z, Lindbäck J, Alexander JH, Bahit MC, De Caterina R, Eikelboom JW, Ezekowitz MD, Gersh BJ, Granger CB, Hylek EM, Lopes R, Siegbahn A, Wallentin L. Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. Open Heart. 2021 03; 8(1). PMID: 33741689; PMCID: PMC7986788; DOI: 10.1136/openhrt-2020-001471;

Hylek EM. The importance of adherence and persistence in the elderly atrial fibrillation patient. Eur Heart J Suppl. 2020 Sep; 22(Suppl I):I38-I42. PMID: 33088233; PMCID: PMC7556744; DOI: 10.1093/eurheartj/suaa103;

Showing 10 of 276 results. Show More

Hijazi Z, Oldgren J, Lindbäck J, Alexander JH, Alings M, De Caterina R, Eikelboom JW, Ezekowitz MD, Held C, Huber K, Hylek EM, Granger CB, Lopes RD, Vinereanu D, Siegbahn A, Wallentin L. Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. JAMA Netw Open. 2020 09 01; 3(9):e2015943. PMID: 32936298; PMCID: PMC7495236; DOI: 10.1001/jamanetworkopen.2020.15943;

Williams BA, Chamberlain AM, Blankenship JC, Hylek EM, Voyce S. Trends in Atrial Fibrillation Incidence Rates Within an Integrated Health Care Delivery System, 2006 to 2018. JAMA Netw Open. 2020 08 03; 3(8):e2014874. PMID: 32857147; PMCID: PMC7455855; DOI: 10.1001/jamanetworkopen.2020.14874;

Aulin J, Hijazi Z, Siegbahn A, Andersson U, Alexander JH, Connolly SJ, Ezekowitz MD, Gersh BJ, Granger CB, Horowitz J, Hylek EM, Lopes RD, Yusuf S, Wallentin L, Oldgren J. Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. J Thromb Haemost. 2020 09; 18(9):2287-2295. PMID: 32510737

Madhavan M, Holmes DN, Piccini JP, Freeman JV, Fonarow GC, Hylek EM, Kowey PR, Mahaffey KW, Pieper K, Peterson ED, Chan PS, Allen LA, Singer DE, Naccarelli GV, Reiffel JA, Steinberg BA, Gersh BJ. Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF). Am J Cardiol. 2020 10 01; 132:66-71. PMID: 32826041

Geurink K, Holmes D, Ezekowitz MD, Pieper K, Fonarow G, Kowey PR, Reiffel JA, Singer DE, Freeman J, Gersh BJ, Mahaffey KW, Hylek EM, Naccarelli G, Piccini JP, Peterson ED, Pokorney SD. Patterns of oral anticoagulation use with cardioversion in clinical practice. Heart. 2021 04; 107(8):642-649. PMID: 32591363

Ko D, Kapoor A, Rose AJ, Hanchate AD, Miller D, Winter MR, Palmisano JN, Henault LE, Fredman L, Walkey AJ, Tripodis Y, Karcz A, Hylek EM. Temporal trends in pharmacologic prophylaxis for venous thromboembolism after hip and knee replacement in older adults. Vasc Med. 2020 10; 25(5):450-459.View Related Profiles.

Rose, Adam
Walkey, Allan
Hanchate, Amresh
Ko, Darae
Hylek, Elaine
Fredman, Lisa
Tripodis, Yorghos

PMID: 32516054; DOI: 10.1177/1358863X20927096;

Røsjø H, Hijazi Z, Omland T, Westerbergh J, Lyngbakken MN, Alexander JH, Gersh BJ, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Wallentin L. Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial. J Intern Med. 2020 08; 288(2):248-259. PMID: 32350915

Jackson LR, Kim S, Blanco R, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Go AS, Kowey PR, Mahaffey KW, Hylek EM, Peterson ED, Piccini JP. Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am Heart J. 2020 08; 226:85-93. PMID: 32526533

Steinberg BA, Holmes DN, Pieper K, Allen LA, Chan PS, Ezekowitz MD, Freeman JV, Fonarow GC, Gersh BJ, Hylek EM, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J, Singer DE, Peterson ED, Piccini JP. Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation: Results From ORBIT-AF. Circ Arrhythm Electrophysiol. 2020 05; 13(5):e007775. PMID: 32298144; PMCID: PMC7247417; DOI: 10.1161/CIRCEP.119.007775;

Inohara T, Holmes DN, Pieper K, Blanco RG, Allen LA, Fonarow GC, Gersh BJ, Hylek EM, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Mahaffey KW, Singer DE, Freeman JV, Steinberg BA, Peterson ED, Piccini JP. Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Heart. 2020 03; 106(5):358-364. PMID: 31911503

Freeman JV, Shrader P, Pieper KS, Allen LA, Chan PS, Fonarow GC, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel JA, Singer DE, Go AS, Hylek EM, Steinberg BA, Peterson ED, Piccini JP. Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. Circ Arrhythm Electrophysiol. 2019 12; 12(12):e007612. PMID: 31830822

Dalgaard F, Mulder H, Wojdyla DM, Lopes RD, Held C, Alexander JH, De Caterina R, Washam JB, Hylek EM, Garcia DA, Gersh BJ, Wallentin L, Granger CB, Al-Khatib SM. Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. Circulation. 2020 01 07; 141(1):10-20. PMID: 31747786

Berglund E, Wallentin L, Oldgren J, Renlund H, Alexander JH, Granger CB, Hohnloser SH, Hylek EM, Lopes RD, McMurray JJ, Lytsy P. Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trial. Eur J Prev Cardiol. 2020 08; 27(12):1311-1319. PMID: 31698965

Eikelboom JW, van Ryn J, Reilly P, Hylek EM, Elsaesser A, Glund S, Pollack CV, Weitz JI. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment. J Am Coll Cardiol. 2019 10 08; 74(14):1760-1768. PMID: 31582135

Pokorney SD, Holmes DN, Thomas L, Fonarow GC, Kowey PR, Reiffel JA, Singer DE, Freeman JV, Gersh BJ, Mahaffey KW, Hylek EM, Naccarelli GV, Ezekowitz MD, Piccini JP, Peterson ED. Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. JAMA Cardiol. 2019 08 01; 4(8):756-764. PMID: 31268487; PMCID: PMC6613340; DOI: 10.1001/jamacardio.2019.1960;

Hylek EM, Anania FA. Oral Anticoagulants in Liver Disease: Not Child's Play. J Am Coll Cardiol. 2019 07 02; 73(25):3309-3311. PMID: 31248552

Guimarães PO, Lopes RD, Alexander JH, Thomas L, Hellkamp AS, Hijazi Z, Hylek EM, Gersh BJ, Garcia DA, Verheugt FWA, Hanna M, Flaker G, Vinereanu D, Granger CB. International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin. J Thromb Thrombolysis. 2019 Jul; 48(1):27-34. PMID: 30972712

Perino AC, Shrader P, Turakhia MP, Ansell JE, Gersh BJ, Fonarow GC, Go AS, Kaiser DW, Hylek EM, Kowey PR, Singer DE, Thomas L, Steinberg BA, Peterson ED, Piccini JP, Mahaffey KW. Comparison of Patient-Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT - AF Registry. J Am Heart Assoc. 2019 05 07; 8(9):e011205. PMID: 31023126; PMCID: PMC6512133; DOI: 10.1161/JAHA.118.011205;

Washam JB, Hohnloser SH, Lopes RD, Wojdyla DM, Vinereanu D, Alexander JH, Gersh BJ, Hanna M, Horowitz J, Hylek EM, Xavier D, Verheugt FWA, Wallentin L, Granger CB. Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. J Thromb Thrombolysis. 2019 Apr; 47(3):345-352. PMID: 30790160

Vemulapalli S, Inohara T, Kim S, Thomas L, Piccini JP, Patel MR, Chang P, Fonarow GC, Ezekowitz MD, Hylek E, Go AS, Kowey PR, Mahaffey KW, Gersh BJ, Peterson ED. Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry). Am J Cardiol. 2019 05 15; 123(10):1628-1636. PMID: 30846214

Renda G, Patti G, Lang IM, Siller-Matula JM, Hylek EM, Ambrosio G, Haas S, De Caterina R. Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies. Int J Cardiol. 2019 07 01; 286:198-207. PMID: 30777407

Hylek EM. Biomarkers for Prediction of Stroke and Bleeds in Atrial Fibrillation. Circulation. 2019 02 05; 139(6):772-774. PMID: 30715942

Madhavan M, Holmes DN, Piccini JP, Ansell JE, Fonarow GC, Hylek EM, Kowey PR, Mahaffey KW, Thomas L, Peterson ED, Chan P, Allen LA, Gersh BJ. Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation. Am Heart J. 2019 05; 211:77-89. PMID: 30901602

De Caterina R, Ageno W, Agnelli G, Chan NC, Diener HC, Hylek E, Raskob GE, Siegal DM, Verheugt FWA, Lip GYH, Weitz JI. The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thromb Haemost. 2019 Jan; 119(1):14-38. PMID: 30597497

Alexander KP, Brouwer MA, Mulder H, Vinereanu D, Lopes RD, Proietti M, Al-Khatib SM, Hijazi Z, Halvorsen S, Hylek EM, Verheugt FWA, Alexander JH, Wallentin L, Granger CB. Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. Am Heart J. 2019 02; 208:123-131. PMID: 30579505

Hylek EM. Treatment Persistence in Atrial Fibrillation: The Next Major Hurdle. Thromb Haemost. 2018 Dec; 118(12):2018-2019. PMID: 30453349

Jackson LR, Kim S, Shrader P, Blanco R, Thomas L, Ezekowitz MD, Ansell J, Fonarow GC, Gersh BJ, Go AS, Kowey PR, Mahaffey KW, Hylek EM, Peterson ED, Piccini JP. Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. J Thromb Thrombolysis. 2018 Nov; 46(4):435-439. PMID: 30051164; PMCID: PMC6182370; DOI: 10.1007/s11239-018-1715-1;

Pokorney SD, Gersh BJ, Ahmad A, Al-Khatib SM, Blank M, Coylewright M, DiBattiste P, Healey JS, Hedrich O, Hylek EM, Kline-Rogers E, Peterson ED, Mendys P, Mirro MJ, Naccarelli G, Patel P, Ruff CT, Rutman H, Stockbridge N, Temple R, Granger CB. Stroke prevention in atrial fibrillation: Closing the gap. Am Heart J. 2019 04; 210:29-38. PMID: 30731371

Sharma A, Hijazi Z, Andersson U, Al-Khatib SM, Lopes RD, Alexander JH, Held C, Hylek EM, Leonardi S, Hanna M, Ezekowitz JA, Siegbahn A, Granger CB, Wallentin L. Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. Circulation. 2018 10 16; 138(16):1666-1676. PMID: 29871978

Hylek EM. Apixaban for End-Stage Kidney Disease. Circulation. 2018 10 09; 138(15):1534-1536. PMID: 30354524

Washam JB, Holmes DN, Thomas LE, Pokorney SD, Hylek EM, Fonarow GC, Mahaffey KW, Gersh BJ, Kowey PR, Ansell JE, Go AS, Reiffel JA, Freeman JV, Singer DE, Naccarelli G, Blanco R, Peterson ED, Piccini JP. Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT-AF. J Am Heart Assoc. 2018 09 18; 7(18):e008928. PMID: 30371218; PMCID: PMC6222961; DOI: 10.1161/JAHA.118.008928;

Christersson C, Wallentin L, Andersson U, Alexander JH, Alings M, De Caterina R, Gersh BJ, Granger CB, Halvorsen S, Hanna M, Huber K, Hylek EM, Lopes RD, Oh BH, Siegbahn A. Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. Heart. 2019 02; 105(3):235-242. PMID: 30209126; PMCID: PMC6388910; DOI: 10.1136/heartjnl-2018-313351;

O'Brien EC, Holmes DN, Thomas LE, Fonarow GC, Allen LA, Gersh BJ, Kowey PR, Singer DE, Ezekowitz MD, Naccarelli GV, Ansell JE, Chan PS, Mahaffey KW, Go AS, Freeman JV, Reiffel JA, Peterson ED, Piccini JP, Hylek EM. Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. Circulation. 2018 08 28; 138(9):889-897. PMID: 29678813

Jackson LR, Kim S, Fonarow GC, Freeman JV, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Singer D, Thomas L, Blanco R, Peterson ED, Piccini JP. Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA2DS2-VASc Scores: Findings From the ORBIT-AF I and II Registries. J Am Heart Assoc. 2018 08 21; 7(16):e008764. PMID: 30369317; PMCID: PMC6201408; DOI: 10.1161/JAHA.118.008764;

Horowitz JD, De Caterina R, Heresztyn T, Alexander JH, Andersson U, Lopes RD, Steg PG, Hylek EM, Mohan P, Hanna M, Jansky P, Granger CB, Wallentin L. Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy. J Am Coll Cardiol. 2018 08 14; 72(7):721-733. PMID: 30092948

Ko D, Razouki Z, Otis J, Marulanda-Londoño E, Hylek EM. Anticoagulation reversal in vitamin K antagonist-associated intracerebral hemorrhage: a systematic review. J Thromb Thrombolysis. 2018 Aug; 46(2):227-237.View Related Profiles.

Ko, Darae
Hylek, Elaine
Otis, James

PMID: 29687299

O'Brien EC, Holmes DN, Thomas L, Singer DE, Fonarow GC, Mahaffey KW, Kowey PR, Hylek EM, Pokorney SD, Ansell JE, Pencina MJ, Peterson ED, Piccini JP. Incremental prognostic value of renal function for stroke prediction in atrial fibrillation. Int J Cardiol. 2019 Jan 01; 274:152-157.View Related Profiles.

Hylek, Elaine
Pencina, Michael

PMID: 30144994

O'Brien EC, Holmes DN, Thomas L, Fonarow GC, Kowey PR, Ansell JE, Mahaffey KW, Gersh BJ, Peterson ED, Piccini JP, Hylek EM. Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT-AF. J Am Heart Assoc. 2018 06 09; 7(12). PMID: 29886422; PMCID: PMC6220555; DOI: 10.1161/JAHA.117.006391;

Durheim MT, Holmes DN, Blanco RG, Allen LA, Chan PS, Freeman JV, Fonarow GC, Go AS, Hylek EM, Mahaffey KW, Pokorney SD, Reiffel JA, Singer DE, Peterson ED, Piccini JP. Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. Heart. 2018 11; 104(22):1850-1858. PMID: 29875139

Lopes RD, Guimarães PO, Crowther M, Hylek E, Feitosa-Filho GS, Ritt LE, Filgueiras N, Garcia DA. Highlights from the Tenth International Symposium of Thrombosis and Anticoagulation (ISTA X), September 22 and 23, 2017, Salvador, Bahia, Brazil. J Thromb Thrombolysis. 2018 May; 45(4):578-587. PMID: 29524111

Fudim M, Liu PR, Shrader P, Blanco RG, Allen LA, Fonarow GC, Gersh BJ, Kowey PR, Mahaffey KW, Hylek E, Go AS, Thomas L, Peterson ED, Piccini JP. Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry. J Am Heart Assoc. 2018 04 13; 7(8). PMID: 29654203; PMCID: PMC6015424; DOI: 10.1161/JAHA.117.007987;

Hijazi Z, Oldgren J, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Yusuf S, Granger CB, Siegbahn A, Wallentin L. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018 02 07; 39(6):477-485. PMID: 29069359; PMCID: PMC5837352; DOI: 10.1093/eurheartj/ehx584;

Aronis KN, Hylek EM. Evidence Gaps in the Era of Non-Vitamin K Oral Anticoagulants. J Am Heart Assoc. 2018 01 26; 7(3). PMID: 29374049; PMCID: PMC5850242; DOI: 10.1161/JAHA.117.007338;

Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK, Nielsen JC, Curtis AB, Davies DW, Day JD, d'Avila A, de Groot NMSN, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, Yamane T. 2017?HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Europace. 2018 01 01; 20(1):157-208.View Related Profiles.

Hylek, Elaine
Helm, Robert

PMID: 29016841; PMCID: PMC5892164; DOI: 10.1093/europace/eux275;

Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK, Cosedis Nielsen J, Curtis AB, Davies DW, Day JD, d'Avila A, Natasja de Groot NMS, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, Yamane T. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018 01 01; 20(1):e1-e160.View Related Profiles.

Hylek, Elaine
Helm, Robert

PMID: 29016840; PMCID: PMC5834122; DOI: 10.1093/europace/eux274;

Rao MP, Vinereanu D, Wojdyla DM, Alexander JH, Atar D, Hylek EM, Hanna M, Wallentin L, Lopes RD, Gersh BJ, Granger CB. Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. Am J Med. 2018 03; 131(3):269-275.e2. PMID: 29122636

Barnett AS, Kim S, Fonarow GC, Thomas LE, Reiffel JA, Allen LA, Freeman JV, Naccarelli G, Mahaffey KW, Go AS, Kowey PR, Ansell JE, Gersh BJ, Hylek EM, Peterson ED, Piccini JP. Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines: Findings From ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation). Circ Arrhythm Electrophysiol. 2017 Nov; 10(11). PMID: 29141842

Lopes RD, Guimarães PO, Hylek E, Feitosa-Filho GS, Ritt L, Filgueiras N, Darzé E, Rocha MS, Magalhães LP, Sousa ACS, Correia LC, Oliveira LH, Garcia DA. Highlights from the Ninth International Symposium of Thrombosis and Anticoagulation (ISTA IX), October 15, 2016, Salvador, Bahia, Brazil. J Thromb Thrombolysis. 2017 Nov; 44(4):544-555. PMID: 28918569

Wendelboe AM, Raskob GE, Angchaisuksiri P, Blanco AN, Büller H, Ddungu H, Dvorak JD, Hunt BJ, Hylek EM, Kakkar A, Konstantinides SV, McCumber M, McLintock C, Urano T, Weitz JI. Global public awareness about atrial fibrillation. Res Pract Thromb Haemost. 2018 Jan; 2(1):49-57. PMID: 30046706; PMCID: PMC6055485; DOI: 10.1002/rth2.12051;

Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK, Nielsen JC, Curtis AB, Wyn Davies D, Day JD, d'Avila A, de Groot NMSN, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, Yamane T. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. J Interv Card Electrophysiol. 2017 Oct; 50(1):1-55.View Related Profiles.

Hylek, Elaine
Helm, Robert

PMID: 28914401; PMCID: PMC5633646; DOI: 10.1007/s10840-017-0277-z;

Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK, Nielsen JC, Curtis AB, Davies DW, Day JD, d'Avila A, de Groot NMSN, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, Yamane T. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. Heart Rhythm. 2017 Oct; 14(10):e445-e494.View Related Profiles.

Hylek, Elaine
Helm, Robert

PMID: 31631881

Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK, Nielsen JC, Curtis AB, Davies DW, Day JD, d'Avila A, de Groot NMSN, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, Yamane T. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. J Arrhythm. 2017 Oct; 33(5):369-409.View Related Profiles.

Hylek, Elaine
Helm, Robert

PMID: 29021841; PMCID: PMC5634725; DOI: 10.1016/j.joa.2017.08.001;

Echouffo-Tcheugui JB, Shrader P, Thomas L, Gersh BJ, Kowey PR, Mahaffey KW, Singer DE, Hylek EM, Go AS, Peterson ED, Piccini JP, Fonarow GC. Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry. J Am Coll Cardiol. 2017 Sep 12; 70(11):1325-1335. PMID: 28882229

Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, Hylek EM, Hanna M, Wallentin L, Gersh BJ, Douglas PS, Alexander JH, Lopes RD. Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. Am J Med. 2017 Dec; 130(12):1440-1448.e1. PMID: 28739198

Pollack CV, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med. 2017 08 03; 377(5):431-441. PMID: 28693366

Melloni C, Shrader P, Carver J, Piccini JP, Thomas L, Fonarow GC, Ansell J, Gersh B, Go AS, Hylek E, Herling IM, Mahaffey KW, Yu AF, Peterson ED, Kowey PR. Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. Eur Heart J Qual Care Clin Outcomes. 2017 07 01; 3(3):192-197. PMID: 28838088

Hijazi Z, Lindahl B, Oldgren J, Andersson U, Lindbäck J, Granger CB, Alexander JH, Gersh BJ, Hanna M, Harjola VP, Hylek EM, Lopes RD, Siegbahn A, Wallentin L. Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. J Am Heart Assoc. 2017 Jun 23; 6(6). PMID: 28645934; PMCID: PMC5669148; DOI: 10.1161/JAHA.116.004851;

Black-Maier E, Kim S, Steinberg BA, Fonarow GC, Freeman JV, Kowey PR, Ansell J, Gersh BJ, Mahaffey KW, Naccarelli G, Hylek EM, Go AS, Peterson ED, Piccini JP. Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. Clin Cardiol. 2017 Sep; 40(9):746-751. PMID: 28543401; PMCID: PMC5638096; DOI: 10.1002/clc.22726;

Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK, Nielsen JC, Curtis AB, Davies DW, Day JD, d'Avila A, de Groot NMSN, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, Yamane T. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017 10; 14(10):e275-e444.View Related Profiles.

Hylek, Elaine
Helm, Robert

PMID: 28506916; PMCID: PMC6019327; DOI: 10.1016/j.hrthm.2017.05.012;

Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Hylek E, Kowey PR, Mahaffey KW, O'Brien EC, Singer DE, Peterson ED, Piccini JP. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am Heart J. 2017 Jul; 189:40-47. PMID: 28625380

Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, Ezekowitz MD, Granger CB, Halperin JL, Hohnloser SH, Hylek EM, Kirchhof P, Lane DA, Verheugt FWA, Veltkamp R, Lip GYH. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J. 2017 Mar 21; 38(12):860-868. PMID: 26848150; PMCID: PMC5837363; DOI: 10.1093/eurheartj/ehw069;

Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, Ezekowitz MD, Granger CB, Halperin JL, Hohnloser SH, Hylek EM, Kirchhof P, Lane DA, Verheugt FWA, Veltkamp R, Lip GYH. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. Eur Heart J. 2017 Mar 21; 38(12):852-859. PMID: 26848149; PMCID: PMC5837588; DOI: 10.1093/eurheartj/ehv643;

Kapoor A, Ellis A, Shaffer N, Gurwitz J, Chandramohan A, Saulino J, Ishak A, Okubanjo T, Michota F, Hylek E, Trikalinos TA. Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis. J Thromb Haemost. 2017 Feb; 15(2):284-294. PMID: 28102615; PMCID: PMC5305416; DOI: 10.1111/jth.13566;

Raimondi P, Hylek EM, Aronis KN. Reversal Agents for Oral Antiplatelet and Anticoagulant Treatment During Bleeding Events: Current Strategies. Curr Pharm Des. 2017; 23(9):1406-1423. PMID: 27917717

Pandey A, Kim S, Moore C, Thomas L, Gersh B, Allen LA, Kowey PR, Mahaffey KW, Hylek E, Peterson ED, Piccini JP, Fonarow GC. Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. JACC Heart Fail. 2017 Jan; 5(1):44-52. PMID: 28034376; DOI: 10.1016/j.jchf.2016.09.016;

Westenbrink BD, Alings M, Granger CB, Alexander JH, Lopes RD, Hylek EM, Thomas L, Wojdyla DM, Hanna M, Keltai M, Steg PG, De Caterina R, Wallentin L, van Gilst WH. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J. 2017 Mar; 185:140-149. PMID: 28267467; DOI: 10.1016/j.ahj.2016.12.008;

Pandey A, Kim S, Moore C, Thomas L, Gersh B, Allen LA, Kowey PR, Mahaffey KW, Hylek E, Peterson ED, Piccini JP, Fonarow GC. Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. JACC Heart Fail. 2016 Nov 30. PMID: 28017349; DOI: 10.1016/j.jchf.2016.09.016;

Fanola CL, Mooney D, Cowan AJ, Ko D, Sisson EK, Henault LE, Tripodis Y, Hylek EM. Incidence of severe renal dysfunction among individuals taking warfarin and implications for non-vitamin K oral anticoagulants. Am Heart J. 2017 Feb; 184:150-155.View Related Profiles.

Ko, Darae
Hylek, Elaine
Tripodis, Yorghos

PMID: 28224930; PMCID: PMC6594157; DOI: 10.1016/j.ahj.2016.08.017;

Ko D, Rahman F, Martins MA, Hylek EM, Ellinor PT, Schnabel RB, Benjamin EJ, Christophersen IE. Atrial fibrillation in women: treatment. Nat Rev Cardiol. 2017 02; 14(2):113-124.View Related Profiles.

Ko, Darae
Hylek, Elaine
Benjamin, Emelia

PMID: 27786235; PMCID: PMC5520636; DOI: 10.1038/nrcardio.2016.171;

Ko D, Thigpen JL, Otis JA, Forster K, Henault L, Quinn E, Tripodis Y, Berger PB, Limdi N, Hylek EM. Influence of statin therapy at time of stroke onset on functional outcome among patients with atrial fibrillation. Int J Cardiol. 2017 Jan 15; 227:808-812.View Related Profiles.

Ko, Darae
Hylek, Elaine
Otis, James
Tripodis, Yorghos

PMID: 28273786; PMCID: PMC5347145; DOI: 10.1016/j.ijcard.2016.10.055;

Bahit MC, Lopes RD, Wojdyla DM, Held C, Hanna M, Vinereanu D, Hylek EM, Verheugt F, Goto S, Alexander JH, Wallentin L, Granger CB. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart. 2017 Apr; 103(8):623-628. PMID: 27798052; PMCID: PMC5529964; DOI: 10.1136/heartjnl-2016-309901;

Pokorney SD, Shrader P, Thomas L, Fonarow GC, Kowey PR, Singer DE, Ansell J, Gersh BJ, Mahaffey KW, Hylek EM, Go AS, Piccini JP, Peterson ED. Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. Circulation. 2016 10 11; 134(15):1122-1124. PMID: 27753615

Hylek EM, Ko D. Atrial Fibrillation and Fall Risk: What Are the Treatment Implications? J Am Coll Cardiol. 2016 09 13; 68(11):1179-1180.View Related Profiles.

Ko, Darae
Hylek, Elaine

PMID: 27609679; DOI: 10.1016/j.jacc.2016.07.714;

Oldgren J, Hijazi Z, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Wallentin L. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation. 2016 Nov 29; 134(22):1697-1707. PMID: 27569438

Pokorney SD, Simon DN, Thomas L, Gersh BJ, Hylek EM, Piccini JP, Peterson ED. Stability of International Normalized Ratios in Patients Taking Long-term Warfarin Therapy. JAMA. 2016 Aug 9; 316(6):661-3. PMID: 27532922; DOI: 10.1001/jama.2016.9356;

Hylek EM. Antithrombotic drug use: scientific breakthroughs, biological limits and physician behaviour. Heart. 2016 12 01; 102(23):1859-1860. PMID: 27504004; DOI: 10.1136/heartjnl-2016-309902;

Piccini JP, Simon DN, Steinberg BA, Thomas L, Allen LA, Fonarow GC, Gersh B, Hylek E, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Spertus JA, Peterson ED. Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men: Two-Year Results From the ORBIT-AF Registry. JAMA Cardiol. 2016 06 01; 1(3):282-91. PMID: 27438106; DOI: 10.1001/jamacardio.2016.0529;

Ruff CT, Ansell JE, Becker RC, Benjamin EJ, Deicicchi DJ, Mark Estes NA, Ezekowitz MD, Fanikos J, Fareed J, Garcia D, Giugliano RP, Goldhaber SZ, Granger C, Healey JS, Hull R, Hylek EM, Libby P, Lopes RD, Mahaffey KW, Mega J, Piazza G, Sasahara AA, Sorond FA, Spyropoulos AC, Walenga JM, Weitz JI. North American Thrombosis Forum, AF Action Initiative Consensus Document. Am J Med. 2016 May; 129(5 Suppl):S1-S29.View Related Profiles.

Hylek, Elaine
Benjamin, Emelia

PMID: 27126598; DOI: 10.1016/j.amjmed.2016.02.001;

Hijazi Z, Oldgren J, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016 Jun 4; 387(10035):2302-11. PMID: 27056738; DOI: 10.1016/S0140-6736(16)00741-8;

Albers GW, Bernstein RA, Brachmann J, Camm J, Easton JD, Fromm P, Goto S, Granger CB, Hohnloser SH, Hylek E, Jaffer AK, Krieger DW, Passman R, Pines JM, Reed SD, Rothwell PM, Kowey PR. Heart Rhythm Monitoring Strategies for Cryptogenic Stroke: 2015 Diagnostics and Monitoring Stroke Focus Group Report. J Am Heart Assoc. 2016 Mar 15; 5(3):e002944. PMID: 27068633; PMCID: PMC4943268; DOI: 10.1161/JAHA.115.002944;

Procter NE, Ball J, Ngo DT, Isenberg JS, Hylek EM, Chirkov YY, Stewart S, Horowitz JD. Gender and tachycardia: independent modulation of platelet reactivity in patients with atrial fibrillation. J Geriatr Cardiol. 2016 Mar; 13(3):202-8. PMID: 27103914; PMCID: PMC4826889; DOI: 10.11909/j.issn.1671-5411.2016.03.005;

Hijazi Z, Lindbäck J, Alexander JH, Hanna M, Held C, Hylek EM, Lopes RD, Oldgren J, Siegbahn A, Stewart RA, White HD, Granger CB, Wallentin L. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016 May 21; 37(20):1582-90. PMID: 26920728; PMCID: PMC4875560; DOI: 10.1093/eurheartj/ehw054;

Gundlund A, Fosbøl EL, Kim S, Fonarow GC, Gersh BJ, Kowey PR, Hylek E, Mahaffey KW, Thomas L, Piccini JP, Peterson ED. Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J. 2016 May; 175:28-35. PMID: 27179721; DOI: 10.1016/j.ahj.2016.01.020;

Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, Ezekowitz MD, Granger CB, Halperin JL, Hohnloser SH, Hylek EM, Kirchhof P, Lane DA, Verheugt FW, Veltkamp R, Lip GY. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. Eur Heart J. 2016 Feb 04. PMID: 28158700; DOI: 10.1093/eurheartj/ehv643;

Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, Ezekowitz MD, Granger CB, Halperin JL, Hohnloser SH, Hylek EM, Kirchhof P, Lane DA, Verheugt FW, Veltkamp R, Lip GY. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J. 2016 Feb 04. PMID: 28158531; DOI: 10.1093/eurheartj/ehw069;

Hijazi Z, Aulin J, Andersson U, Alexander JH, Gersh B, Granger CB, Hanna M, Horowitz J, Hylek EM, Lopes RD, Siegbahn A, Wallentin L. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart. 2016 Apr; 102(7):508-17. PMID: 26839066; DOI: 10.1136/heartjnl-2015-308887;

Aronis KN, Hylek EM. Who, when, and how to reverse non-vitamin K oral anticoagulants. J Thromb Thrombolysis. 2016 Feb; 41(2):253-72. PMID: 26627486; DOI: 10.1007/s11239-015-1297-0;

De Caterina R, Andersson U, Alexander JH, Al-Khatib SM, Bahit MC, Goto S, Hanna M, Held C, Hohnloser S, Hylek EM, Lanas F, Lopes RD, López-Sendón J, Renda G, Horowitz J, Granger CB, Wallentin L. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J. 2016 May; 175:175-83. PMID: 27179738; DOI: 10.1016/j.ahj.2016.01.005;

Lopes RD, Rao M, Simon DN, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Go AS, Hylek EM, Kowey P, Piccini JP, Singer DE, Chang P, Peterson ED, Mahaffey KW. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. Am J Med. 2016 Jun; 129(6):592-599.e1. PMID: 26797080; DOI: 10.1016/j.amjmed.2015.12.026;

Levy JH, Weitz JI, Bernstein RA, Eikelboom J, Hylek E, Huisman MV, Reilly PA, Steiner T, Kamphuisen P, Kam CW, Pollack CV. Letter to the Editor: Managing Dabigatran-Related Bleeding. J Intensive Care Med. 2016 Jan; 31(1):70-1. PMID: 26663474; DOI: 10.1177/0885066614542758;

Golwala H, Jackson LR, Simon DN, Piccini JP, Gersh B, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Thomas L, Fonarow GC, Peterson ED, Thomas KL. Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. Am Heart J. 2016 Apr; 174:29-36. PMID: 26995367; DOI: 10.1016/j.ahj.2015.10.028;

Pandey A, Gersh BJ, McGuire DK, Shrader P, Thomas L, Kowey PR, Mahaffey KW, Hylek E, Sun S, Burton P, Piccini J, Peterson E, Fonarow GC. Association of Body Mass Index With Care and Outcomes in Patients With Atrial Fibrillation: Results From the ORBIT-AF Registry. JACC Clin Electrophysiol. 2016 Jun; 2(3):355-363. PMID: 29766895

Rao MP, Halvorsen S, Wojdyla D, Thomas L, Alexander JH, Hylek EM, Hanna M, Bahit MC, Lopes RD, De Caterina R, Erol C, Goto S, Lanas F, Lewis BS, Husted S, Gersh BJ, Wallentin L, Granger CB. Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. J Am Heart Assoc. 2015 Dec; 4(12). PMID: 26627878; PMCID: PMC4845276; DOI: 10.1161/JAHA.115.002015;

Witt DM, Clark NP, Martinez K, Schroeder A, Garcia D, Crowther MA, Ageno W, Dentali F, Ye X, Hylek E, Delate T. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage. Thromb Res. 2015 Nov; 136(5):1040-4. PMID: 26454758; DOI: 10.1016/j.thromres.2015.10.002;

Triller DM, Wymer S, Meek PD, Hylek EM, Ansell JE. Trends in Warfarin Monitoring Practices Among New York Medicare Beneficiaries, 2006-2011. J Community Health. 2015 Oct; 40(5):845-54. PMID: 26198584; DOI: 10.1007/s10900-015-0066-5;

O'Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, Kowey PR, Mahaffey KW, Chang P, Fonarow GC, Pencina MJ, Piccini JP, Peterson ED. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015 Dec 7; 36(46):3258-64.View Related Profiles.

Hylek, Elaine
Pencina, Michael

PMID: 26424865; PMCID: PMC4670965; DOI: 10.1093/eurheartj/ehv476;

Steinberg BA, Kim S, Thomas L, Fonarow GC, Gersh BJ, Holmqvist F, Hylek E, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel JA, Chang P, Peterson ED, Piccini JP. Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF). J Am Heart Assoc. 2015 Sep; 4(9):e002031. PMID: 26370445; PMCID: PMC4599492; DOI: 10.1161/JAHA.115.002031;

Vinereanu D, Stevens SR, Alexander JH, Al-Khatib SM, Avezum A, Bahit MC, Granger CB, Lopes RD, Halvorsen S, Hanna M, Husted S, Hylek EM, Margulescu AD, Wallentin L, Atar D. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. Eur Heart J. 2015 Dec 7; 36(46):3268-75. PMID: 26371113; DOI: 10.1093/eurheartj/ehv447;

Aronis KN, Thigpen JL, Tripodis Y, Dillon C, Forster K, Henault L, Quinn EK, Berger PB, Limdi NA, Hylek EM. Paroxysmal atrial fibrillation and the hazards of under-treatment. Int J Cardiol. 2016 Jan 1; 202:214-20.View Related Profiles.

Hylek, Elaine
Tripodis, Yorghos

PMID: 26397414; PMCID: PMC5527994; DOI: 10.1016/j.ijcard.2015.09.006;

Wendelboe AM, McCumber M, Hylek EM, Buller H, Weitz JI, Raskob G. Global public awareness of venous thromboembolism. J Thromb Haemost. 2015 Aug; 13(8):1365-71. PMID: 26084415; DOI: 10.1111/jth.13031;

Andreotti F, Rocca B, Husted S, Ajjan RA, ten Berg J, Cattaneo M, Collet JP, De Caterina R, Fox KA, Halvorsen S, Huber K, Hylek EM, Lip GY, Montalescot G, Morais J, Patrono C, Verheugt FW, Wallentin L, Weiss TW, Storey RF. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J. 2015 Dec 7; 36(46):3238-49. PMID: 26163482; DOI: 10.1093/eurheartj/ehv304;

Procter NE, Ball J, Ngo DT, Chirkov YY, Isenberg JS, Hylek EM, Stewart S, Horowitz JD. Platelet hyperaggregability in patients with atrial fibrillation. Evidence of a background proinflammatory milieu. Herz. 2016 Feb; 41(1):57-62.View Related Profiles.

Ngo, Doan
Hylek, Elaine

PMID: 26135468; DOI: 10.1007/s00059-015-4335-y;

Allen LA, Fonarow GC, Simon DN, Thomas LE, Marzec LN, Pokorney SD, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Chang P, Peterson ED, Piccini JP. Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. J Am Coll Cardiol. 2015 Jun 30; 65(25):2691-8. PMID: 26112191; PMCID: PMC4483195; DOI: 10.1016/j.jacc.2015.04.045;

Lane DA, Aguinaga L, Blomström-Lundqvist C, Boriani G, Dan GA, Hills MT, Hylek EM, LaHaye SA, Lip GY, Lobban T, Mandrola J, McCabe PJ, Pedersen SS, Pisters R, Stewart S, Wood K, Potpara TS, Gorenek B, Conti JB, Keegan R, Power S, Hendriks J, Ritter P, Calkins H, Violi F, Hurwitz J. Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace. 2015 Dec; 17(12):1747-69. PMID: 26108807; DOI: 10.1093/europace/euv233;

Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015 Aug 6; 373(6):511-20. PMID: 26095746; DOI: 10.1056/NEJMoa1502000;

Freeman JV, Simon DN, Go AS, Spertus J, Fonarow GC, Gersh BJ, Hylek EM, Kowey PR, Mahaffey KW, Thomas LE, Chang P, Peterson ED, Piccini JP. Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes. 2015 Jul; 8(4):393-402. PMID: 26058720; DOI: 10.1161/CIRCOUTCOMES.114.001303;

Pollack CV, Reilly PA, Bernstein R, Dubiel R, Eikelboom J, Glund S, Huisman MV, Hylek E, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Sellke F, Stangier J, Steiner T, Wang B, Weitz JI. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost. 2015 Jul; 114(1):198-205. PMID: 26020620; DOI: 10.1160/TH15-03-0192;

Kim EJ, Ozonoff A, Hylek EM, Berlowitz DR, Ash AS, Miller DR, Zhao S, Reisman JI, Jasuja GK, Rose AJ. Predicting outcomes among patients with atrial fibrillation and heart failure receiving anticoagulation with warfarin. Thromb Haemost. 2015 Jul; 114(1):70-7.View Related Profiles.

Rose, Adam
Ozonoff, Alexander
Berlowitz, Dan
Hylek, Elaine
Jasuja, Guneet

PMID: 25948532; DOI: 10.1160/TH14-09-0754;

Sico JJ, Chang CC, So-Armah K, Justice AC, Hylek E, Skanderson M, McGinnis K, Kuller LH, Kraemer KL, Rimland D, Bidwell Goetz M, Butt AA, Rodriguez-Barradas MC, Gibert C, Leaf D, Brown ST, Samet J, Kazis L, Bryant K, Freiberg MS. HIV status and the risk of ischemic stroke among men. Neurology. 2015 May 12; 84(19):1933-40.View Related Profiles.

Hylek, Elaine
Samet, Jeffrey
So-Armah, Kaku
Kazis, Lewis

PMID: 25862803; PMCID: PMC4433456; DOI: 10.1212/WNL.0000000000001560;

Pokorney SD, Simon DN, Thomas L, Fonarow GC, Kowey PR, Chang P, Singer DE, Ansell J, Blanco RG, Gersh B, Mahaffey KW, Hylek EM, Go AS, Piccini JP, Peterson ED. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am Heart J. 2015 Jul; 170(1):141-8, 148.e1. PMID: 26093875; DOI: 10.1016/j.ahj.2015.03.017;

Holmqvist F, Guan N, Zhu Z, Kowey PR, Allen LA, Fonarow GC, Hylek EM, Mahaffey KW, Freeman JV, Chang P, Holmes DN, Peterson ED, Piccini JP, Gersh BJ. Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2015 May; 169(5):647-654.e2. PMID: 25965712; DOI: 10.1016/j.ahj.2014.12.024;

Ko D, Hylek EM. Left atrial appendage closure for stroke prevention in atrial fibrillation: response to an unmet need with an unclear direction. Circ Arrhythm Electrophysiol. 2015 Feb; 8(1):8-10.View Related Profiles.

Ko, Darae
Hylek, Elaine

PMID: 25691551; DOI: 10.1161/CIRCEP.115.002634;

Thigpen JL, Dillon C, Forster KB, Henault L, Quinn EK, Tripodis Y, Berger PB, Hylek EM, Limdi NA. Validity of international classification of disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2015 Jan; 8(1):8-14.View Related Profiles.

Hylek, Elaine
Tripodis, Yorghos

PMID: 25587093; PMCID: PMC4654947; DOI: 10.1161/CIRCOUTCOMES.113.000371;

Ko D, Magnani JW, Hylek EM. Biomarkers in lone atrial fibrillation - an additional 'fine tuning' of risk? Curr Pharm Des. 2015; 21(5):646-58.View Related Profiles.

Ko, Darae
Hylek, Elaine
Magnani, Jared

PMID: 25175091

Held C, Hylek EM, Alexander JH, Hanna M, Lopes RD, Wojdyla DM, Thomas L, Al-Khalidi H, Alings M, Xavier D, Ansell J, Goto S, Ruzyllo W, Rosenqvist M, Verheugt FW, Zhu J, Granger CB, Wallentin L. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J. 2015 May 21; 36(20):1264-72. PMID: 25499871; DOI: 10.1093/eurheartj/ehu463;

Hijazi Z, Siegbahn A, Andersson U, Lindahl B, Granger CB, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJ, Wallentin L. Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. Clin Chem. 2015 Feb; 61(2):368-78. PMID: 25451868; DOI: 10.1373/clinchem.2014.226936;

Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, Hylek EM, Kakkar A, Konstantinides SV, McCumber M, Ozaki Y, Wendelboe A, Weitz JI. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014 Nov; 34(11):2363-71. PMID: 25304324; DOI: 10.1161/ATVBAHA.114.304488;

Procter NE, Ball J, Liu S, Hurst N, Nooney VB, Goh V, Stafford I, Heresztyn T, Carrington M, Ngo DT, Hylek EM, Isenberg JS, Chirkov YY, Stewart S, Horowitz JD. Impaired platelet nitric oxide response in patients with new onset atrial fibrillation. Int J Cardiol. 2015 Jan 20; 179:160-5.View Related Profiles.

Ngo, Doan
Hylek, Elaine

PMID: 25464437; DOI: 10.1016/j.ijcard.2014.10.137;

Garcia D, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M, Al-Khatib SM, Dorian P, Ansell J, Commerford P, Flaker G, Lanas F, Vinereanu D, Xavier D, Hylek EM, Held C, Verheugt FW, Granger CB, Lopes RD. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood. 2014 Dec 11; 124(25):3692-8. PMID: 25320240; PMCID: PMC4263979; DOI: 10.1182/blood-2014-08-595496;

Flaker G, Lopes RD, Hylek E, Wojdyla DM, Thomas L, Al-Khatib SM, Sullivan RM, Hohnloser SH, Garcia D, Hanna M, Amerena J, Harjola VP, Dorian P, Avezum A, Keltai M, Wallentin L, Granger CB. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol. 2014 Oct 14; 64(15):1541-50. PMID: 25301455; DOI: 10.1016/j.jacc.2014.07.967;

Raskob GE, Angchaisuksiri P, Blanco AN, Büller H, Gallus A, Hunt BJ, Hylek EM, Kakkar TL, Konstantinides SV, McCumber M, Ozaki Y, Wendelboe A, Weitz JI. Thrombosis: a major contributor to global disease burden. Semin Thromb Hemost. 2014 Oct; 40(7):724-35. PMID: 25302681; DOI: 10.1055/s-0034-1390325;

Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD, Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014 Nov 18; 130(21):1847-58. PMID: 25294786; DOI: 10.1161/CIRCULATIONAHA.114.011204;

Granger CB, Lopes RD, Hanna M, Ansell J, Hylek EM, Alexander JH, Thomas L, Wang J, Bahit MC, Verheugt F, Lawrence J, Xavier D, Wallentin L. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J. 2015 Jan; 169(1):25-30. PMID: 25497244; DOI: 10.1016/j.ahj.2014.09.006;

Kwaan HC, McMahon BJ, Hylek EM. Age-related changes in thrombosis and hemostasis. Semin Thromb Hemost. 2014 Sep; 40(6):619-20. PMID: 25259875; DOI: 10.1055/s-0034-1390152;

Ko D, Hylek EM. Anticoagulation in the older adult: optimizing benefit and reducing risk. Semin Thromb Hemost. 2014 Sep; 40(6):688-94.View Related Profiles.

Ko, Darae
Hylek, Elaine

PMID: 25184500; DOI: 10.1055/s-0034-1389083;

Christersson C, Wallentin L, Andersson U, Alexander JH, Ansell J, De Caterina R, Gersh BJ, Granger CB, Hanna M, Horowitz JD, Huber K, Husted S, Hylek EM, Lopes RD, Siegbahn A. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial. J Thromb Haemost. 2014 Sep; 12(9):1401-12. PMID: 24942912; DOI: 10.1111/jth.12638;

Efird LM, Mishkin DS, Berlowitz DR, Ash AS, Hylek EM, Ozonoff A, Reisman JI, Zhao S, Jasuja GK, Rose AJ. Stratifying the risks of oral anticoagulation in patients with liver disease. Circ Cardiovasc Qual Outcomes. 2014 May; 7(3):461-7.View Related Profiles.

Rose, Adam
Ozonoff, Alexander
Berlowitz, Dan
Hylek, Elaine
Jasuja, Guneet

PMID: 24823958; DOI: 10.1161/CIRCOUTCOMES.113.000817;

Lip GY, Camm AJ, Hylek EM, Halperin JL, Weitz JI. Non-vitamin K antagonist oral anticoagulants: an appeal for consensus on terminology. Chest. 2014 May; 145(5):1177-8. PMID: 24798856; DOI: 10.1378/chest.13-2951;

Hess PL, Mirro MJ, Diener HC, Eikelboom JW, Al-Khatib SM, Hylek EM, Bosworth HB, Gersh BJ, Singer DE, Flaker G, Mega JL, Peterson ED, Rumsfeld JS, Steinberg BA, Kakkar AK, Califf RM, Granger CB. Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. Am Heart J. 2014 Sep; 168(3):239-247.e1. PMID: 25173533; PMCID: PMC4269555; DOI: 10.1016/j.ahj.2014.04.007;

Steinberg BA, Blanco RG, Ollis D, Kim S, Holmes DN, Kowey PR, Fonarow GC, Ansell J, Gersh B, Go AS, Hylek E, Mahaffey KW, Thomas L, Chang P, Peterson ED, Piccini JP. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. Am Heart J. 2014 Aug; 168(2):160-7. PMID: 25066554; PMCID: PMC4145241; DOI: 10.1016/j.ahj.2014.04.005;

Steinhubl SR, Eikelboom JW, Hylek EM, Dauerman HL, Smyth SS, Becker RC. Antiplatelet therapy in prevention of cardio- and venous thromboembolic events. J Thromb Thrombolysis. 2014 Apr; 37(3):362-71. PMID: 24221804; DOI: 10.1007/s11239-013-1023-8;

Steinberg BA, Kim S, Thomas L, Fonarow GC, Hylek E, Ansell J, Go AS, Chang P, Kowey P, Gersh BJ, Mahaffey KW, Singer DE, Piccini JP, Peterson ED. Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation. 2014 May 20; 129(20):2005-12. PMID: 24682387; PMCID: PMC4050636; DOI: 10.1161/CIRCULATIONAHA.114.008643;

Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, Huber K, Jansky P, Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol. 2014 May 27; 63(20):2141-7. PMID: 24657685; DOI: 10.1016/j.jacc.2014.02.549;

Rao SR, Reisman JI, Kressin NR, Berlowitz DR, Ash AS, Ozonoff A, Miller DR, Hylek EM, Zhao S, Rose AJ. Explaining racial disparities in anticoagulation control: results from a study of patients at the Veterans Administration. Am J Med Qual. 2015 May; 30(3):214-22.View Related Profiles.

Rose, Adam
Ozonoff, Alexander
Berlowitz, Dan
Hylek, Elaine
Kressin, Nancy

PMID: 24642366; DOI: 10.1177/1062860614526282;

Clark NP, Delate T, Riggs CS, Witt DM, Hylek EM, Garcia DA, Ageno W, Dentali F, Crowther MA. Warfarin interactions with antibiotics in the ambulatory care setting. JAMA Intern Med. 2014 Mar; 174(3):409-16. PMID: 24445404; DOI: 10.1001/jamainternmed.2013.13957;

Hylek EM, Ko D, Cove CL. Gaps in translation from trials to practice: non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation. Thromb Haemost. 2014 May 5; 111(5):783-8.View Related Profiles.

Ko, Darae
Hylek, Elaine

PMID: 24573511; DOI: 10.1160/TH13-12-1032;

Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB, Hanna M, Held C, Husted S, Hylek EM, Jansky P, Lopes RD, Ruzyllo W, Thomas L, Wallentin L. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014 Jul 21; 35(28):1864-72. PMID: 24561548; PMCID: PMC4104493; DOI: 10.1093/eurheartj/ehu046;

Paradise HT, Berlowitz DR, Ozonoff A, Miller DR, Hylek EM, Ash AS, Jasuja GK, Zhao S, Reisman JI, Rose AJ. Outcomes of anticoagulation therapy in patients with mental health conditions. J Gen Intern Med. 2014 Jun; 29(6):855-61.View Related Profiles.

Rose, Adam
Ozonoff, Alexander
Berlowitz, Dan
Hylek, Elaine
Jasuja, Guneet

PMID: 24549520; PMCID: PMC4026501; DOI: 10.1007/s11606-014-2784-2;

Steinberg BA, Kim S, Fonarow GC, Thomas L, Ansell J, Kowey PR, Mahaffey KW, Gersh BJ, Hylek E, Naccarelli G, Go AS, Reiffel J, Chang P, Peterson ED, Piccini JP. Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014 May; 167(5):735-42.e2. PMID: 24766985; PMCID: PMC4006943; DOI: 10.1016/j.ahj.2014.02.003;

Hylek EM. The gender gap in academic leadership. Rev Clin Esp (Barc). 2014 Mar; 214(2):83-4. PMID: 24513082; DOI: 10.1016/j.rce.2014.01.013;

Dlott JS, George RA, Huang X, Odeh M, Kaufman HW, Ansell J, Hylek EM. National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation. 2014 Apr 1; 129(13):1407-14. PMID: 24493817; DOI: 10.1161/CIRCULATIONAHA.113.002601;

Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz J, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB. Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation". Circulation. 2014 Jan 14; 129(2):e21-2. PMID: 24421367; DOI: 10.1161/CIRCULATIONAHA.113.005709;

Cancino RS, Hylek EM, Reisman JI, Rose AJ. Comparing patient-level and site-level anticoagulation control as predictors of adverse events. Thromb Res. 2014 Apr; 133(4):652-6.View Related Profiles.

Rose, Adam
Hylek, Elaine
Cancino, Ramon

PMID: 24502961; DOI: 10.1016/j.thromres.2014.01.013;

O'Brien EC, Holmes DN, Ansell JE, Allen LA, Hylek E, Kowey PR, Gersh BJ, Fonarow GC, Koller CR, Ezekowitz MD, Mahaffey KW, Chang P, Peterson ED, Piccini JP, Singer DE. Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J. 2014 Apr; 167(4):601-609.e1. PMID: 24655711; DOI: 10.1016/j.ahj.2013.12.014;

Cove CL, Albert CM, Andreotti F, Badimon L, Van Gelder IC, Hylek EM. Female sex as an independent risk factor for stroke in atrial fibrillation: possible mechanisms. Thromb Haemost. 2014 Mar 3; 111(3):385-91. PMID: 24305974; DOI: 10.1160/TH13-04-0347;

Steinberg BA, Holmes DN, Piccini JP, Ansell J, Chang P, Fonarow GC, Gersh B, Mahaffey KW, Kowey PR, Ezekowitz MD, Singer DE, Thomas L, Peterson ED, Hylek EM. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc. 2013; 2(6):e000535. PMID: 24275632; PMCID: PMC3886732; DOI: 10.1161/JAHA.113.000535;

Hijazi Z, Siegbahn A, Andersson U, Granger CB, Alexander JH, Atar D, Gersh BJ, Mohan P, Harjola VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJ, Wallentin L. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014 Feb 11; 129(6):625-34. PMID: 24226808; DOI: 10.1161/CIRCULATIONAHA.113.006286;

Cove CL, Hylek EM. An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. J Am Heart Assoc. 2013 Oct; 2(5):e000136. PMID: 24152980; PMCID: PMC3835217; DOI: 10.1161/JAHA.113.000136;

Witt DM, Delate T, Hylek EM, Clark NP, Crowther MA, Dentali F, Ageno W, Martinez KD, Garcia DA. Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes. Thromb Res. 2013; 132(6):770-5. PMID: 24521790; DOI: 10.1016/j.thromres.2013.10.024;

Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz JD, Husted S, Hylek EM, Lopes RD, McMurray JJ, Granger CB. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol. 2014 Jan 7-14; 63(1):52-61. PMID: 24055845; DOI: 10.1016/j.jacc.2013.07.093;

Hylek EM. Dabigatran and mechanical heart valves--not as easy as we hoped. N Engl J Med. 2013 Sep 26; 369(13):1264-6. PMID: 23991659

Garcia DA, Wallentin L, Lopes RD, Thomas L, Alexander JH, Hylek EM, Ansell J, Hanna M, Lanas F, Flaker G, Commerford P, Xavier D, Vinereanu D, Yang H, Granger CB. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J. 2013 Sep; 166(3):549-58. PMID: 24016506; DOI: 10.1016/j.ahj.2013.05.016;

Magnani JW, Hylek EM, Apovian CM. Obesity begets atrial fibrillation: a contemporary summary. Circulation. 2013 Jul 23; 128(4):401-5.View Related Profiles.

Apovian, Caroline
Hylek, Elaine
Magnani, Jared

PMID: 23877062; PMCID: PMC3866045; DOI: 10.1161/CIRCULATIONAHA.113.001840;

Steinberg BA, Kim S, Piccini JP, Fonarow GC, Lopes RD, Thomas L, Ezekowitz MD, Ansell J, Kowey P, Singer DE, Gersh B, Mahaffey KW, Hylek E, Go AS, Chang P, Peterson ED. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2013 Aug 13; 128(7):721-8. PMID: 23861512; PMCID: PMC3908483; DOI: 10.1161/CIRCULATIONAHA.113.002927;

Lopes RD, Becker RC, Newby LK, Peterson ED, Hylek EM, Giugliano R, Granger CB, Mahaffey KW, Carvalho AC, Berwanger O, Giraldez RR, Feitosa-Filho GS, Barbosa MM, da Consolacao V Moreira M, Kalil RA, Freitas M, de Campos Guerra JC, Barros MV, da Rocha Rodrigues T, Lopes AC, Garcia DA. Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil. J Thromb Thrombolysis. 2013 Jul; 36(1):115-30. PMID: 23494487; DOI: 10.1007/s11239-013-0906-z;

Witt DM, Delate T, Clark NP, Garcia DA, Hylek EM, Ageno W, Dentali F, Crowther MA. Nonadherence with INR monitoring and anticoagulant complications. Thromb Res. 2013 Aug; 132(2):e124-30. PMID: 23800635; DOI: 10.1016/j.thromres.2013.06.006;

Cullen MW, Kim S, Piccini JP, Ansell JE, Fonarow GC, Hylek EM, Singer DE, Mahaffey KW, Kowey PR, Thomas L, Go AS, Lopes RD, Chang P, Peterson ED, Gersh BJ. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes. 2013 Jul; 6(4):461-9. PMID: 23759473; DOI: 10.1161/CIRCOUTCOMES.113.000127;

Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz JD, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013 Jun 4; 127(22):2166-76. PMID: 23640971; DOI: 10.1161/CIRCULATIONAHA.112.142158;

Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ, Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EM, Lopes RD, McMurray JJ, Granger CB. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol. 2013 Jun 4; 61(22):2274-84. PMID: 23563134; DOI: 10.1016/j.jacc.2012.11.082;

Guyatt G, Eikelboom J, Crowther M, Akl E, Francis C, Garcia D, Gould M, Hylek E, Kahn S, Kunz R, Quinlan D, Vandvik P, Hirsh J. A response to--there's madness in their methods. J Thromb Haemost. 2013 Apr; 11(4):785-6. PMID: 23406024; DOI: 10.1111/jth.12142;

Hylek EM. Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement. J Thromb Thrombolysis. 2013 Apr; 35(3):333-5. PMID: 23456572; DOI: 10.1007/s11239-013-0900-5;

Kapoor A, Chew P, Silliman RA, Hylek EM, Katz JN, Cabral H, Berlowitz D. Venous thromboembolism after joint replacement in older male veterans with comorbidity. J Am Geriatr Soc. 2013 Apr; 61(4):590-601.View Related Profiles.

Kapoor, Alok
Berlowitz, Dan
Hylek, Elaine
Cabral, Howard
Silliman, Rebecca

PMID: 23581913; PMCID: PMC3734860; DOI: 10.1111/jgs.12161;

Rose AJ, Miller DR, Ozonoff A, Berlowitz DR, Ash AS, Zhao S, Reisman JI, Hylek EM. Gaps in monitoring during oral anticoagulation: insights into care transitions, monitoring barriers, and medication nonadherence. Chest. 2013 Mar; 143(3):751-7.View Related Profiles.

Rose, Adam
Ozonoff, Alexander
Berlowitz, Dan
Miller, Donald
Hylek, Elaine

PMID: 23187457; PMCID: PMC5991554; DOI: 10.1378/chest.12-1119;

Hylek EM. Anticoagulation therapy for atrial fibrillation. Semin Thromb Hemost. 2013 Mar; 39(2):147-52. PMID: 23397554; DOI: 10.1055/s-0033-1334812;

Hanchate AD, Schwamm LH, Huang W, Hylek EM. Comparison of ischemic stroke outcomes and patient and hospital characteristics by race/ethnicity and socioeconomic status. Stroke. 2013 Feb; 44(2):469-76.View Related Profiles.

Hanchate, Amresh
Hylek, Elaine

PMID: 23306327; PMCID: PMC3595403; DOI: 10.1161/STROKEAHA.112.669341;

Jasuja GK, Reisman JI, Miller DR, Berlowitz DR, Hylek EM, Ash AS, Ozonoff A, Zhao S, Rose AJ. Identifying major hemorrhage with automated data: results of the Veterans Affairs study to improve anticoagulation (VARIA). Thromb Res. 2013 Jan; 131(1):31-6.View Related Profiles.

Rose, Adam
Ozonoff, Alexander
Berlowitz, Dan
Miller, Donald
Hylek, Elaine
Jasuja, Guneet

PMID: 23158402; DOI: 10.1016/j.thromres.2012.10.010;

Witt DM, Delate T, Garcia DA, Clark NP, Hylek EM, Ageno W, Dentali F, Crowther MA. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med. 2012 Oct 22; 172(19):1484-91. PMID: 22987143; DOI: 10.1001/archinternmed.2012.4261;

Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, De Caterina R, Dorian P, Easton JD, Erol C, Ezekowitz JA, Gersh BJ, Granger CB, Hohnloser SH, Horowitz J, Hylek EM, McMurray JJ, Mohan P, Vinereanu D, Alexander JH. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012 Nov 17; 380(9855):1749-58. PMID: 23036896; DOI: 10.1016/S0140-6736(12)60986-6;

Hlatky MA, Douglas PS, Cook NL, Wells B, Benjamin EJ, Dickersin K, Goff DC, Hirsch AT, Hylek EM, Peterson ED, Roger VL, Selby JV, Udelson JE, Lauer MS. Future directions for cardiovascular disease comparative effectiveness research: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2012 Aug 14; 60(7):569-80.View Related Profiles.

Hylek, Elaine
Benjamin, Emelia

PMID: 22796257; PMCID: PMC3416944; DOI: 10.1016/j.jacc.2011.12.057;

Lopes RD, Becker RC, Newby LK, Peterson ED, Hylek EM, Granger CB, Crowther M, Wang T, Carvalho AC, Berwanger O, Giraldez RR, Feitosa GS, Ribeiro JP, Darze E, Kalil RA, Andrande M, Boas FV, Andrade J, Rocha AT, Harrington RA, Lopes AC, Garcia DA. Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil. J Thromb Thrombolysis. 2012 Jul; 34(1):143-63. PMID: 22427055; DOI: 10.1007/s11239-012-0700-3;

Rose AJ, Berlowitz DR, Miller DR, Hylek EM, Ozonoff A, Zhao S, Reisman JI, Ash AS. INR targets and site-level anticoagulation control: results from the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost. 2012 Apr; 10(4):590-5.View Related Profiles.

Rose, Adam
Ozonoff, Alexander
Berlowitz, Dan
Hylek, Elaine

PMID: 22288563; DOI: 10.1111/j.1538-7836.2012.04649.x;

Rose AJ, Petrakis BA, Callahan P, Mambourg S, Patel D, Hylek EM, Bokhour BG. Organizational characteristics of high- and low-performing anticoagulation clinics in the Veterans Health Administration. Health Serv Res. 2012 Aug; 47(4):1541-60.View Related Profiles.

Rose, Adam
Bokhour, Barbara
Hylek, Elaine

PMID: 22299722; PMCID: PMC3401398; DOI: 10.1111/j.1475-6773.2011.01377.x;

Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; 141(2 Suppl):e44S-88S. PMID: 22315269; PMCID: PMC3278051; DOI: 10.1378/chest.11-2292;

You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GY. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; 141(2 Suppl):e531S-75S. PMID: 22315271; PMCID: PMC3278056; DOI: 10.1378/chest.11-2304;

Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marín F, Palareti G, Kirchhof P. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost. 2011 Dec; 106(6):997-1011. PMID: 22048796; DOI: 10.1160/TH11-10-0690;

Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kääb S, Schotten U, Wegscheider K, Boriani G, Ezekowitz M, Diener H, Heidbuchel H, Lane D, Mont L, Willems S, Dorian P, Vardas P, Breithardt G, Camm AJ. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. Thromb Haemost. 2011 Dec; 106(6):1012-9. PMID: 22048744; DOI: 10.1160/TH11-07-0517;

Piccini JP, Fraulo ES, Ansell JE, Fonarow GC, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Thomas LE, Kong MH, Lopes RD, Mills RM, Peterson ED. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J. 2011 Oct; 162(4):606-612.e1. PMID: 21982650; DOI: 10.1016/j.ahj.2011.07.001;

Lopes RD, Horowitz JD, Garcia DA, Crowther MA, Hylek EM. Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility. Blood. 2011 Dec 8; 118(24):6269-73. PMID: 21911832; PMCID: PMC5524527; DOI: 10.1182/blood-2011-08-335612;

De Caterina R, Hylek EM. Stroke prevention in atrial fibrillation: current status and near-future directions. Am J Med. 2011 Sep; 124(9):793-9. PMID: 21745652; DOI: 10.1016/j.amjmed.2011.03.013;

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15; 365(11):981-92. PMID: 21870978; DOI: 10.1056/NEJMoa1107039;

Lopes RD, Becker RC, Alexander JH, Armstrong PW, Califf RM, Chan MY, Crowther M, Granger CB, Harrington RA, Hylek EM, James SK, Jolicoeur EM, Mahaffey KW, Newby LK, Peterson ED, Pieper KS, Van de Werf F, Wallentin L, White HD, Carvalho AC, Giraldez RR, Guimaraes HP, Nader HB, Kalil RA, Bizzachi JM, Lopes AC, Garcia DA. Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil. J Thromb Thrombolysis. 2011 Aug; 32(2):242-66. PMID: 21547405; DOI: 10.1007/s11239-011-0592-7;

Dentali F, Marchesi C, Pierfranceschi MG, Crowther M, Garcia D, Hylek E, Witt DM, Clark NP, Squizzato A, Imberti D, Ageno W. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost. 2011 Sep; 106(3):429-38. PMID: 21800002; DOI: 10.1160/TH11-01-0052;

Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, Schotten U, Wegscheider K, Boriani G, Brandes A, Ezekowitz M, Diener H, Haegeli L, Heidbuchel H, Lane D, Mont L, Willems S, Dorian P, Aunes-Jansson M, Blomstrom-Lundqvist C, Borentain M, Breitenstein S, Brueckmann M, Cater N, Clemens A, Dobrev D, Dubner S, Edvardsson NG, Friberg L, Goette A, Gulizia M, Hatala R, Horwood J, Szumowski L, Kappenberger L, Kautzner J, Leute A, Lobban T, Meyer R, Millerhagen J, Morgan J, Muenzel F, Nabauer M, Baertels C, Oeff M, Paar D, Polifka J, Ravens U, Rosin L, Stegink W, Steinbeck G, Vardas P, Vincent A, Walter M, Breithardt G, Camm AJ. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace. 2012 Jan; 14(1):8-27. PMID: 21791573; PMCID: PMC3236658; DOI: 10.1093/europace/eur241;

Rose AJ, Berlowitz DR, Ash AS, Ozonoff A, Hylek EM, Goldhaber-Fiebert JD. The business case for quality improvement: oral anticoagulation for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2011 Jul; 4(4):416-24.View Related Profiles.

Rose, Adam
Ozonoff, Alexander
Berlowitz, Dan
Hylek, Elaine

PMID: 21712521; PMCID: PMC3967019; DOI: 10.1161/CIRCOUTCOMES.111.960591;

Estes NA, Sacco RL, Al-Khatib SM, Ellinor PT, Bezanson J, Alonso A, Antzelevitch C, Brockman RG, Chen PS, Chugh SS, Curtis AB, DiMarco JP, Ellenbogen KA, Epstein AE, Ezekowitz MD, Fayad P, Gage BF, Go AS, Hlatky MA, Hylek EM, Jerosch-Herold M, Konstam MA, Lee R, Packer DL, Po SS, Prystowsky EN, Redline S, Rosenberg Y, Van Wagoner DR, Wood KA, Yue L, Benjamin EJ. American Heart Association atrial fibrillation research summit: a conference report from the American Heart Association. Circulation. 2011 Jul 19; 124(3):363-72.View Related Profiles.

Hylek, Elaine
Benjamin, Emelia

PMID: 21709057; PMCID: PMC3144149; DOI: 10.1161/CIR.0b013e318224b037;

Dentali F, Gianni M, Squizzato A, Ageno W, Castiglioni L, Maroni L, Hylek EM, Grandi AM, Cazzani E, Venco A, Guasti L. Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion. A systematic review and meta-analysis. Thromb Haemost. 2011 Aug; 106(2):363-70. PMID: 21614408; DOI: 10.1160/TH10-10-0660;

Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane DA, Levi M, Marin F, Palareti G, Kirchhof P, Collet JP, Rubboli A, Poli D, Camm J. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace. 2011 May; 13(5):723-46. PMID: 21515596; DOI: 10.1093/europace/eur126;

Rose AJ, Hylek EM, Berlowitz DR, Ash AS, Reisman JI, Ozonoff A. Prompt repeat testing after out-of-range INR values: a quality indicator for anticoagulation care. Circ Cardiovasc Qual Outcomes. 2011 May; 4(3):276-82.View Related Profiles.

Rose, Adam
Ozonoff, Alexander
Berlowitz, Dan
Hylek, Elaine

PMID: 21505156; DOI: 10.1161/CIRCOUTCOMES.110.960096;

Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Callahan PP, Gordon MM, Berlowitz DR. Relevance of current guidelines for organizing an anticoagulation clinic. Am J Manag Care. 2011 Apr; 17(4):284-9.View Related Profiles.

Rose, Adam
Ozonoff, Alexander
Berlowitz, Dan
Hylek, Elaine

PMID: 21615198

Dentali F, Donadini MP, Clark N, Crowther MA, Garcia D, Hylek E, Witt DM, Ageno W. Brand name versus generic warfarin: a systematic review of the literature. Pharmacotherapy. 2011 Apr; 31(4):386-93. PMID: 21449627; DOI: 10.1592/phco.31.4.386;

Cabral KP, Ansell J, Hylek EM. Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification. J Thromb Haemost. 2011 Mar; 9(3):441-9. PMID: 21176102; DOI: 10.1111/j.1538-7836.2010.04179.x;

Rose AJ, Ozonoff A, Berlowitz DR, Ash AS, Reisman JI, Hylek EM. Reexamining the recommended follow-up interval after obtaining an in-range international normalized ratio value: results from the Veterans Affairs study to improve anticoagulation. Chest. 2011 Aug; 140(2):359-65.View Related Profiles.

Rose, Adam
Ozonoff, Alexander
Berlowitz, Dan
Hylek, Elaine

PMID: 21310837; DOI: 10.1378/chest.10-2738;

Hylek EM. Therapeutic potential of oral factor Xa inhibitors. N Engl J Med. 2010 Dec 23; 363(26):2559-61. PMID: 21175319; DOI: 10.1056/NEJMe1012149;

Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes. 2011 Jan 1; 4(1):22-9.View Related Profiles.

Rose, Adam
Ozonoff, Alexander
Berlowitz, Dan
Hylek, Elaine

PMID: 21098779; DOI: 10.1161/CIRCOUTCOMES.110.957738;

Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost. 2010 Oct; 8(10):2182-91.View Related Profiles.

Rose, Adam
Ozonoff, Alexander
Berlowitz, Dan
Hylek, Elaine

PMID: 20653840; DOI: 10.1111/j.1538-7836.2010.03996.x;

Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost. 2010 Dec; 104(6):1099-105. PMID: 20886196; DOI: 10.1160/TH10-07-0491;

Rose AJ, Hylek EM. High blood pressure while taking antithrombotic medication is associated with an increased risk of developing intracranial haemorrhage. Evid Based Med. 2010 Dec; 15(6):189-90.View Related Profiles.

Rose, Adam
Hylek, Elaine

PMID: 20797990; DOI: 10.1136/ebm1123;

Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, Garcia DA, Ageno W, Hylek EM. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. J Thromb Haemost. 2010 Apr; 8(4):744-9. PMID: 20398186; DOI: 10.1111/j.1538-7836.2010.03756.x;

Cowan A, Hylek EM. Bleeding risk on warfarin among elderly patients with atrial fibrillation. J Am Coll Cardiol. 2010 Mar 2; 55(9):932; author reply 932-3. PMID: 20185052; DOI: 10.1016/j.jacc.2009.11.037;

Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010 Mar; 159(3):331-9. PMID: 20211292; DOI: 10.1016/j.ahj.2009.07.035;

Rose AJ, Ozonoff A, Henault LE, Hylek EM. Anticoagulation for valvular heart disease in community-based practice. Thromb Haemost. 2010 Feb; 103(2):329-37.View Related Profiles.

Rose, Adam
Ozonoff, Alexander
Hylek, Elaine

PMID: 20024499; DOI: 10.1160/TH09-07-0450;

Hylek EM. Antithrombotic prophylaxis in elderly patients with atrial fibrillation. Semin Thromb Hemost. 2009 Sep; 35(6):548-53. PMID: 19787558; DOI: 10.1055/s-0029-1240015;

Rose AJ, Ozonoff A, Grant RW, Henault LE, Hylek EM. Epidemiology of subtherapeutic anticoagulation in the United States. Circ Cardiovasc Qual Outcomes. 2009 Nov; 2(6):591-7.View Related Profiles.

Rose, Adam
Ozonoff, Alexander
Hylek, Elaine

PMID: 20031897; DOI: 10.1161/CIRCOUTCOMES.109.862763;

Witt DM, Delate T, McCool KH, Dowd MB, Clark NP, Crowther MA, Garcia DA, Ageno W, Dentali F, Hylek EM, Rector WG. Incidence and predictors of bleeding or thrombosis after polypectomy in patients receiving and not receiving anticoagulation therapy. J Thromb Haemost. 2009 Dec; 7(12):1982-9. PMID: 19719825; DOI: 10.1111/j.1538-7836.2009.03598.x;

Hylek EM. The need for new oral anticoagulants in clinical practice. J Cardiovasc Med (Hagerstown). 2009 Aug; 10(8):605-9. PMID: 19571764; DOI: 10.2459/JCM.0b013e32832e4954;

Garcia DA, Hylek E. Warfarin pharmacogenetics. N Engl J Med. 2009 Jun 4; 360(23):2474; author reply 2475. PMID: 19494226; DOI: 10.1056/NEJMc090579;

Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, Garcia DA, Ageno W, Hylek EM. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood. 2009 Jul 30; 114(5):952-6. PMID: 19439733; DOI: 10.1182/blood-2009-02-207928;

Lopes RD, Becker RC, Garcia D, Hylek EM, Granger CB, Lourenço DM, Nader HB, Maffei FH, Cesena FH, Nicolau JC, Timmerman A, Rocha AT, de Paiva EF, Guimaraes HP, Carvalho AC, D'Amico EA, Moreira-Filho CA, Aldrighi JM, Lopes AC. Highlights from the I international symposium of thrombosis and anticoagulation in internal medicine, October 23-25, 2008, Sao Paulo, Brazil. J Thromb Thrombolysis. 2009 Jul; 28(1):106-16. PMID: 19322521; DOI: 10.1007/s11239-009-0324-4;

Hylek EM, Rose AJ. Understanding low INR in clinical practice. Thromb Haemost. 2009 Mar; 101(3):417-8.View Related Profiles.

Rose, Adam
Hylek, Elaine

PMID: 19277399

Rose AJ, Berlowitz DR, Frayne SM, Hylek EM. Measuring quality of oral anticoagulation care: extending quality measurement to a new field. Jt Comm J Qual Patient Saf. 2009 Mar; 35(3):146-55.View Related Profiles.

Rose, Adam
Berlowitz, Dan
Hylek, Elaine

PMID: 19326806

Freedman JE, Hylek EM. Clopidogrel, genetics, and drug responsiveness. N Engl J Med. 2009 Jan 22; 360(4):411-3.View Related Profiles.

Hylek, Elaine
Freedman, Jane

PMID: 19164193; DOI: 10.1056/NEJMe0810513;

Hylek EM, Becker RC. Atrial fibrillation and stroke severity: expanding the mechanistic exemplar, clinical phenotype, and goals of anticoagulant pharmacotherapy. Ann Neurol. 2008 Nov; 64(5):480-3. PMID: 19067369; DOI: 10.1002/ana.21551;

Rose AJ, Ozonoff A, Berlowitz DR, Henault LE, Hylek EM. Warfarin dose management affects INR control. J Thromb Haemost. 2009 Jan; 7(1):94-101.View Related Profiles.

Rose, Adam
Ozonoff, Alexander
Berlowitz, Dan
Hylek, Elaine

PMID: 18983486; DOI: 10.1111/j.1538-7836.2008.03199.x;

Rose AJ, Ozonoff A, Henault LE, Hylek EM. Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost. 2008 Oct; 6(10):1647-54.View Related Profiles.

Rose, Adam
Ozonoff, Alexander
Hylek, Elaine

PMID: 18853483

Hylek EM. Oral anticoagulant therapy for patients with atrial fibrillation--an update. Thromb Res. 2008; 123 Suppl 1:S46-9. PMID: 18809205; DOI: 10.1016/j.thromres.2008.08.016;

Lopes RD, Piccini JP, Hylek EM, Granger CB, Alexander JH. Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician. J Thromb Thrombolysis. 2008 Dec; 26(3):167-74. PMID: 18807225; DOI: 10.1007/s11239-008-0272-4;

Hylek EM, Frison L, Henault LE, Cupples A. Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V. Stroke. 2008 Nov; 39(11):3009-14.View Related Profiles.

Hylek, Elaine
Cupples, L

PMID: 18703812; DOI: 10.1161/STROKEAHA.108.514935;

Clark NP, Witt DM, Delate T, Trapp M, Garcia D, Ageno W, Hylek EM, Crowther MA. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study. Pharmacotherapy. 2008 Aug; 28(8):960-7. PMID: 18657012; DOI: 10.1592/phco.28.8.960;

Hylek EM. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation. Thromb Haemost. 2008 Jul; 100(1):16-7. PMID: 18612532; DOI: 10.1160/TH08-06-0343;

Garcia DA, Witt DM, Hylek E, Wittkowsky AK, Nutescu EA, Jacobson A, Moll S, Merli GJ, Crowther M, Earl L, Becker RC, Oertel L, Jaffer A, Ansell JE. Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother. 2008 Jul; 42(7):979-88. PMID: 18559954; DOI: 10.1345/aph.1L098;

Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):160S-198S. PMID: 18574265; DOI: 10.1378/chest.08-0670;

Garcia DA, Hylek E. Reducing the risk for stroke in patients who have atrial fibrillation. Cardiol Clin. 2008 May; 26(2):267-75, vii. PMID: 18406999; DOI: 10.1016/j.ccl.2007.12.011;

Jagsi R, Tarbell NJ, Henault LE, Chang Y, Hylek EM. The representation of women on the editorial boards of major medical journals: a 35-year perspective. Arch Intern Med. 2008 Mar 10; 168(5):544-8. PMID: 18332302; DOI: 10.1001/archinte.168.5.544;

Hylek EM, Solarz DE. Dual antiplatelet and oral anticoagulant therapy: increasing use and precautions for a hazardous combination. JACC Cardiovasc Interv. 2008 Feb; 1(1):62-4. PMID: 19393146; DOI: 10.1016/j.jcin.2007.11.005;

Bussey HI, Wittkowsky AK, Hylek EM, Walker MB. Genetic testing for warfarin dosing? Not yet ready for prime time. Pharmacotherapy. 2008 Feb; 28(2):141-3. PMID: 18225960; DOI: 10.1592/phco.28.2.141;

Garcia DA, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, Hylek EM. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008 Jan 14; 168(1):63-9.View Related Profiles.

Upadhyay, Ashish
Hylek, Elaine

PMID: 18195197; DOI: 10.1001/archinternmed.2007.23;

Hylek EM, Magnani JW. Methodological considerations for interpretation of rates of major haemorrhage in studies of anticoagulant therapy for atrial fibrillation. Europace. 2008 Jan; 10(1):3-5.View Related Profiles.

Hylek, Elaine
Magnani, Jared

PMID: 18039690

Hylek E. DU-176b, an oral, direct Factor Xa antagonist. Curr Opin Investig Drugs. 2007 Sep; 8(9):778-83. PMID: 17729190

Garcia D, Hylek E. Stroke prevention in elderly patients with atrial fibrillation. Lancet. 2007 Aug 11; 370(9586):460-1. PMID: 17693158

Evans-Molina C, Regan S, Henault LE, Hylek EM, Schwartz GR. The new Medicare Part D prescription drug benefit: an estimation of its effect on prescription drug costs in a Medicare population with atrial fibrillation. J Am Geriatr Soc. 2007 Jul; 55(7):1038-43. PMID: 17608876; PMCID: PMC4067009; DOI: 10.1111/j.1532-5415.2007.01285.x;

Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, Singer DE. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007 Aug; 120(8):700-5. PMID: 17679129; PMCID: PMC3534961; DOI: 10.1016/j.amjmed.2006.07.034;

Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007 May 29; 115(21):2689-96. PMID: 17515465

Rose AJ, Sharman JP, Ozonoff A, Henault LE, Hylek EM. Effectiveness of warfarin among patients with cancer. J Gen Intern Med. 2007 Jul; 22(7):997-1002.View Related Profiles.

Rose, Adam
Ozonoff, Alexander
Hylek, Elaine

PMID: 17476542; PMCID: PMC2219727; DOI: 10.1007/s11606-007-0228-y;

Garcia D, Hylek E. A risk model predicted major bleeding in older patients with atrial fibrillation receiving warfarin therapy. Evid Based Med. 2007 Apr; 12(2):57. PMID: 17400649

Garcia D, Hylek E. A risk model predicted major bleeding in older patients with atrial fibrillation receiving warfarin therapy. ACP J Club. 2007 Mar-Apr; 146(2):52. PMID: 17335175

Hylek EM. Does preadmission anticoagulation therapy reduce stroke severity in patients with atrial fibrillation? Nat Clin Pract Cardiovasc Med. 2007 Apr; 4(4):186-7. PMID: 17290231

Fang MC, Go AS, Hylek EM, Chang Y, Henault LE, Jensvold NG, Singer DE. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc. 2006 Aug; 54(8):1231-6. PMID: 16913990; PMCID: PMC3534958; DOI: 10.1111/j.1532-5415.2006.00828.x;

Jagsi R, Guancial EA, Worobey CC, Henault LE, Chang Y, Starr R, Tarbell NJ, Hylek EM. The "gender gap" in authorship of academic medical literature--a 35-year perspective. N Engl J Med. 2006 Jul 20; 355(3):281-7. PMID: 16855268

Hylek EM, D'Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke. 2006 Apr; 37(4):1075-80. PMID: 16527999

Garcia DA, Hylek EM. Antithrombotic therapy in atrial fibrillation. Clin Geriatr Med. 2006 Feb; 22(1):155-66, x. PMID: 16377472

Garcia DA, Regan S, Crowther M, Hylek EM. The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol. 2006 Feb 21; 47(4):804-8. PMID: 16487849

Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, Raskob G, Lewis SZ, Schünemann H. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest. 2006 Jan; 129(1):174-81. PMID: 16424429

Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, Go AS. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005 Sep 20; 112(12):1687-91. PMID: 16157766; PMCID: PMC3522521; DOI: 10.1161/CIRCULATIONAHA.105.553438;

Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest. 2005 Jun; 127(6):2049-56. PMID: 15947319

Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, Singer DE. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004 Nov 16; 141(10):745-52. PMID: 15545674

Hylek EM. Paracetamol (acetaminophen) and warfarin interaction: unraveling the pivotal role of the vitamin K cycle. Thromb Haemost. 2004 Oct; 92(4):672-3. PMID: 15467892

Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):204S-233S. PMID: 15383473

Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby JV, Singer DE. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003 Nov 26; 290(20):2685-92. PMID: 14645310

Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003 Sep 11; 349(11):1019-26. PMID: 12968085

Hylek EM. Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factors. Semin Vasc Med. 2003 Aug; 3(3):271-8. PMID: 15199460

Hylek EM. Trends in anticoagulation management across community-based practices in the United States: the Anticoagulation Consortium to Improve Outcomes Nationally (ACTION) study. J Thromb Thrombolysis. 2003 Aug-Oct; 16(1-2):83-6. PMID: 14760219

Hylek EM, Regan S, Henault LE, Gardner M, Chan AT, Singer DE, Barry MJ. Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis. Arch Intern Med. 2003 Mar 10; 163(5):621-7. PMID: 12622610

Go AS, Reed GL, Hylek EM, Phillips KA, Liu L, Henault LE, Selby JV, Singer DE. Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Thromb Thrombolysis. 2003 Feb; 15(1):41-6. PMID: 14574075

Smith EE, Rosand J, Knudsen KA, Hylek EM, Greenberg SM. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology. 2002 Jul 23; 59(2):193-7. PMID: 12136056

Hylek EM, Regan S, Go AS, Hughes RA, Singer DE, Skates SJ. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med. 2001 Sep 18; 135(6):393-400. PMID: 11560452

Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9; 285(18):2370-5. PMID: 11343485

Hylek EM. Oral anticoagulants. Pharmacologic issues for use in the elderly. Clin Geriatr Med. 2001 Feb; 17(1):1-13. PMID: 11270124

Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology. 2000 Oct 10; 55(7):947-51. PMID: 11061249

Go AS, Hylek EM, Phillips KA, Borowsky LH, Henault LE, Chang Y, Selby JV, Singer DE. Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation. 2000 Jul 4; 102(1):11-3. PMID: 10880408

Hylek EM, Chang YC, Skates SJ, Hughes RA, Singer DE. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med. 2000 Jun 12; 160(11):1612-7. PMID: 10847254

Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999 Dec 21; 131(12):927-34. PMID: 10610643

Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 1998 Mar 4; 279(9):657-62. PMID: 9496982

Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996 Aug 22; 335(8):540-6. PMID: 8678931

Singer DE, Hylek EM. Optimal oral anticoagulation for patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995 Nov 30; 333(22):1504. PMID: 7477157

Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994 Jun 1; 120(11):897-902. PMID: 8172435

Hylek EM. How the doctor got gagged. JAMA. 1992 Jul 1; 268(1):50-1. PMID: 1472193

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 276 publications over 30 distinct years, with a maximum of 30 publications in 2014

Bar chart showing 276 publications over 30 distinct years, with a maximum of 30 publications in 2014

Year	Publications
1992	1
1994	1
1995	1
1996	1
1998	1
1999	1
2000	3
2001	3
2002	1
2003	6
2004	3
2005	2
2006	6
2007	10
2008	15
2009	11
2010	8
2011	18
2012	9
2013	21
2014	30
2015	24
2016	25
2017	20
2018	22
2019	13
2020	11
2021	4
2022	3
2023	2

Media Mentions

Catheter-directed fibrinolysis safe in intermediate-high-risk pulmonary embolism

Healio 12/16/2022

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

TCTMD 11/11/2022

Catheter-Directed Thrombolysis Promising for Intermediate-Risk Pulmonary Embolism

MedPage Today 10/19/2022

Fitbit Joins the AF Hunt, but Effect on Treatment, Outcomes Unknown

tctMD 11/14/2021

No increase in atrial arrhythmias, more activity, less sleep with coffee consumption

Healio 11/14/2021

Coffee Causes This One Arrhythmia, Trial Shows

Medpage Today 11/14/2021

RIVER: Rivaroxaban Rivals Warfarin in Atrial Fib With Bioprosthetic Mitral Valves

Medscape 11/15/2020

2011-2011 Other: Awarded Best Doctors in America 2007, 2009, 2011

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Antithrombotic Therapy
Atrial Fibrillation
Intracranial Hemorrhage
Stroke
Thrombosis

Available to Mentor as: (Review Mentor Role Definitions):

Advisor
Career Mentor
Co-Mentor or Peer Mentor
Project Mentor
Research / Scholarly Mentor

Contact for Mentoring:

801 Massachusetts Ave Crosstown Center
Boston MA 02118
Google Map

617.414.3743

Download vCard

Hylek's Networks

Click the "See All" links for more information and interactive visualizations

Concepts

See all (467) concept(s)

Media Mentions

Co-Authors

See all (18) people

Similar People

See all (60) people

Same Department

Search Department